Spinal Anaplastic Oligodendroglioma With Oligodendrogliomatosis: Molecular Markers and Management: Case Report.
BACKGROUND
Spinal cord oligodendrogliomas are rare tumors, with a reported incidence varying between 0.8% and 4.7% of all spinal cord tumors and just over 50 cases reported in the literature. Of these, only 9 cases are histologically defined as anaplastic oligodendrogliomas, with few having complete molecular characterization. The diffuse tumor spread that can occur along the subarachnoid space with secondary invasion of the leptomeninges is called oligodendrogliomatosis and is associated with poor outcome.


METHODS
A 68-year-old man with a history of lumbar stenosis status after lumbar decompression presented with new-onset right lower-extremity weakness. Magnetic resonance imaging demonstrated an intramedullary lesion from T9 to T12. During an attempted diagnostic biopsy, numerous intradural intramedullary lesions not present on magnetic resonance imaging were observed. Tissue biopsy demonstrated a 1p/19q-codeleted anaplastic oligodendroglioma with diffuse oligodendrogliomatosis. Postoperative treatment included 39.2-Gy radiation over 22 fractions from T1 to the bottom of the thecal sac with a boost to the T9-T12 area, the primary site of disease, to a total dose of 43.2 Gy in 24 fractions, followed by adjuvant temozolomide at a dose of 200 mg/m on days 1 to 5 in a 28-day cycle. At the 1-year follow-up, the patient demonstrated moderate neurological improvement.


CONCLUSIONS
Management, prognosis, and use of molecular data in the decision-making algorithm for these patients are discussed, together with a review of all cases of primary intradural intramedullary spinal anaplastic oligodendrogliomas reported to date. Our study indicates that the combination of sequential treatment with radiation and temozolomide might provide a favorable outcome in the case of 1p/19q-codeleted spinal anaplastic oligodendrogliomas and that molecular analysis can be beneficial in guiding treatment strategies, although the impact of IDH mutations on these tumors is still unclear.
*Departments of Neurosurgery, ¶Pathology, Section of Neuropathology, ‖Neuro-Oncology, #Radiation Oncology, and **Neuroradiology, University of Texas MD Anderson Cancer Center, Houston, Texas; ‡Department of Neurosurgery, Medical University of South Carolina, Charleston, South Carolina; §Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas; ‡‡Current: Department of Neurosurgery, The Keck School of Medicine of the University of Southern California, Los Angeles, California.
Ben A
BA
Strickland
David
D
Cachia
Ali
A
Jalali
Matthew D
MD
Cykowski
Marta
M
Penas-Prado
Lauren A
LA
Langford
Jing
J
Li
Komal
K
Shah
Jeffrey S
JS
Weinberg
D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage; D059248:Chemoradiotherapy / Q000379:methods*; D003606:Dacarbazine / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D009837:Oligodendroglioma / Q000235:genetics / Q000473:pathology* / Q000628:therapy*; D013120:Spinal Cord Neoplasms / Q000235:genetics / Q000473:pathology* / Q000628:therapy*; D000077204:Temozolomide
D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide